文献速递肝病

高剂量质子泵抑制剂与肝硬化患者死亡率升高相关:多中心研究

High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.
PubMed 文献 · Aliment Pharmacol Ther · 2024-02-22

该多中心回顾性队列纳入韩国7家转诊中心1485例曾发生肝性脑病的肝硬化患者,比较平均限定日剂量≥0.5的高剂量PPI组与<0.5的无/低剂量组。高剂量PPI独立关联死亡风险升高(aHR=1.71)及复发性HE、SBP、消化道出血风险增加,倾向评分匹配后结果可重复。

要点

  • 高剂量PPI与肝硬化患者死亡风险独立相关,匹配后aHR达1.90
  • 高剂量PPI增加复发性肝性脑病和自发性细菌性腹膜炎风险
  • 高剂量PPI与消化道出血风险升高相关,HRS关联在匹配后不显著

核心结论

  • 高剂量PPI使用与肝硬化患者死亡率和肝硬化并发症风险升高独立相关。

研究设计与样本

  • 多中心回顾性队列研究,纳入韩国7家转诊中心1485例曾发生肝性脑病的肝硬化患者。
  • 高剂量PPI组定义为平均限定日剂量≥0.5,对照组为无或低剂量PPI(mDDD<0.5)。
  • 主要结局为总生存,次要结局包括复发性HE、SBP、HRS和消化道出血。

主要发现

  • 高剂量PPI独立关联死亡风险升高(aHR=1.71,95%CI 1.38-2.11,p<0.001),PSM后aHR=1.90(95%CI 1.49-2.44,p<0.001)。
  • 高剂量PPI为复发性HE独立危险因素(PSM前aHR=2.04,95%CI 1.66-2.51,p<0.001;PSM后aHR=2.16,95%CI 1.70-2.74,p<0.001)。
  • 高剂量PPI与SBP风险升高相关(PSM前aHR=1.87,95%CI 1.43-2.43,p<0.001;PSM后aHR=1.76,95%CI 1.31-2.36,p=0.002)。
  • 高剂量PPI与消化道出血风险升高相关(PSM前aHR=1.46,95%CI 1.12-1.90,p=0.006;PSM后aHR=1.74,95%CI 1.28-2.37,p<0.001)。
  • HRS关联在PSM前有统计学意义(aHR=1.48,95%CI 1.02-2.15,p=0.04),PSM后无统计学意义(aHR=1.47,95%CI 0.95-2.28,p=0.09)。

临床怎么用

  • 对肝硬化患者应审慎评估PPI使用指征,避免不必要的高剂量长期使用。
  • 使用高剂量PPI的肝硬化患者需关注死亡、复发性HE、SBP及消化道出血风险。

局限性

  • 本研究为回顾性队列研究,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proton pump inhibitors (PPI) are frequently used in patients with cirrhosis. AIMS: This study aimed to determine whether PPI use is associated with the prognosis of cirrhotic patients. METHODS: We conducted a multicentre retrospective cohort study involving 1485 patients who had experienced hepatic encephalopathy (HE) from 7 referral centres in Korea. The primary outcome was overall survival and secondary outcomes included the development of cirrhotic complications, including recurrent HE, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and gastrointestinal bleeding. Patients treated with PPI with a mean defined daily dose (mDDD) ≥0.5 (high-dose PPI group) were compared to those treated with PPI of an mDDD < 0.5 (No or low-dose PPI group) for each outcome. RESULTS: Among 1485 patients (median age, 61 years; male, 61%), 232 were assigned to the high-dose PPI group. High-dose PPI use was independently associated with a higher risk of death (adjusted HR [aHR] = 1.71, 95% confidence interval [CI] = 1.38-2.11, p < 0.001). This result was reproducible after propensity score-matching (PSM) (aHR = 1.90, 95% CI = 1.49-2.44, p < 0.001). High-dose PPI use was an independent risk factor of recurrent HE (before PSM: aHR = 2.04, 95% CI = 1.66-2.51, p < 0.001; after PSM: aHR = 2.16, 95% CI = 1.70-2.74, p < 0.001), SBP (before PSM: aHR = 1.87, 95% CI = 1.43-2.43, p < 0.001; after PSM: aHR = 1.76, 95% CI = 1.31-2.36, p = 0.002), HRS (before PSM: aHR = 1.48, 95% CI = 1.02-2.15, p = 0.04; after PSM: aHR = 1.47, 95% CI = 0.95-2.28, p = 0.09), and gastrointestinal bleeding (before PSM: aHR = 1.46, 95% CI = 1.12-1.90, p = 0.006; after PSM: aHR = 1.74, 95% CI = 1.28-2.37, p < 0.001). CONCLUSIONS: The use of high-dose PPI was independently associated with increased risks of mortality and cirrhotic complications.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yoon JS, Hong JH, Park SY, et al. High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study. Aliment Pharmacol Ther. 2024. PMID: 38389319. doi:10.1111/apt.17909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。